Augmentation strategies for treatment-resistant obsessive-compulsive disorder

Area of Science:

• Psychiatry and Behavioral Sciences
• Clinical Psychology
• Pharmacology

Background:

• Obsessive-compulsive disorder (OCD) frequently presents with treatment resistance.
• Factors contributing to treatment failure include noncompliance, comorbid disorders (e.g., depression, personality disorders), and diagnostic inaccuracies.
• Effective management of OCD requires addressing these underlying issues.

Purpose of the Study:

• To review augmentation strategies for patients with treatment-resistant obsessive-compulsive disorder (OCD).
• To explore the role of various augmenting agents in managing refractory OCD.
• To highlight the importance of diagnosing and treating comorbid psychiatric conditions.

Main Methods:

• Literature review of augmentation strategies for treatment-resistant OCD.
• Clinical experience with augmenting agents including lithium, buspirone, clonidine, fenfluramine, antidepressants, anxiolytics, and neuroleptics.
• Analysis of factors contributing to treatment non-response in OCD patients.

Main Results:

• Several augmentation strategies show potential utility for specific patient subgroups with treatment-resistant OCD.
• Comorbid psychiatric disorders significantly impact treatment outcomes and require dedicated management.
• Evidence suggests that agents like lithium and certain antidepressants may benefit some patients.

Conclusions:

• Augmentation strategies can be beneficial for select patients with treatment-resistant OCD.
• Thorough assessment for and treatment of comorbid conditions are crucial.
• Further research is essential to optimize augmentation protocols and address remaining questions in OCD management.